MCID: PRT036
MIFTS: 65

Peritonitis

Categories: Endocrine diseases, Gastrointestinal diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Peritonitis

MalaCards integrated aliases for Peritonitis:

Name: Peritonitis 12 74 54 6 15 17 71 32
Retractile Mesenteritis 12 20 71
Sclerosing Mesenteritis 12 20 71
Peritoneal Retractile Mesenteritis 20 71
Acute Generalized Peritonitis 12 71
Primary Bacterial Peritonitis 12 71
Mesenteric Panniculitis 20 71
Idiopathic Sclerosing Mesenteritis 20
Liposclerotic Mesenteritis 20
Mesenteric Lipodystrophy 20
Mesenteric Lipogranuloma 20
Mesenteric Fibromatosis 20
Fibromatosis, Abdominal 71

Classifications:



External Ids:

Disease Ontology 12 DOID:8283
ICD9CM 34 567.8
SNOMED-CT 67 197183001
ICD10 32 K65 K65.9
UMLS 71 C0025470 C0029823 C0031154 more

Summaries for Peritonitis

GARD : 20 Sclerosing mesenteritis is one of many terms that describes a spectrum of inflammatory disorders that affect the mesentery. The mesentery is the membrane that anchors the small intestine to the back of the abdominal wall. The condition mostly affects men between their 40s and 60s, but women and children can also be affected. It may result in a variety of symptoms including abdominal pain, nausea and vomiting, constipation or diarrhea, weight loss, and fever. Some people have an abdominal mass. The cause of the condition is poorly understood. Suggested possible causes have included previous abdominal surgery or trauma, autoimmunity, paraneoplastic syndromes, ischemic injury, and infection. Treatment depends on the symptoms in each person and may include the use of glucocorticoids, hormonal therapy (tamoxifen or progesterone), or other medications, either alone or in combination (i.e. glucocorticoids in combination with tamoxifen). Surgery may be needed for an obstruction, if present. Although there are case reports of patients with aggressive disease and fatalities, it appears that the condition usually remains stable or is slowly progessive. In some cases, the condition goes away on its own.

MalaCards based summary : Peritonitis, also known as retractile mesenteritis, is related to tuberculous peritonitis and appendicitis. An important gene associated with Peritonitis is TMEM67 (Transmembrane Protein 67), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Acetylcysteine and Lactulose have been mentioned in the context of this disorder. Affiliated tissues include colon, neutrophil and small intestine, and related phenotypes are cardiovascular system and cellular

Disease Ontology : 12 A gastrointestinal system disease that involves inflammation of the peritoneum resulting from perforation of the gastrointestinal tract, which produces immediate chemical inflammation followed shortly by infection from intestinal organisms. Peritonitis can also result from appendicitis, diverticulitis, strangulating intestinal obstruction, pancreatitis, pelvic inflammatory disease, mesenteric ischemia, intraperitoneal blood, barium, or peritoneo-systemic shunts, drains, and dialysis catheters in the peritoneal cavity. The symptoms include abdominal pain and tenderness, fever, fluid in the abdomen, nausea, vomiting and low urine output.

Wikipedia : 74 Peritonitis is inflammation of the peritoneum, the lining of the inner wall of the abdomen and cover of... more...

Related Diseases for Peritonitis

Diseases related to Peritonitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1384)
# Related Disease Score Top Affiliating Genes
1 tuberculous peritonitis 32.9 MUC16 CRP ALB ADA
2 appendicitis 32.4 TNF LBP IL6 IL1B IL10 CXCL8
3 familial mediterranean fever 32.1 TNF TLR2 MEFV IL6 IL1B IL10
4 ascaris lumbricoides infection 32.1 IL6 IL1B CXCL8
5 amebiasis 31.9 TNF TLR2 IL1B IL10 CXCL8 ALB
6 intestinal obstruction 31.8 IL6 CRP ALB
7 systemic onset juvenile idiopathic arthritis 31.7 TNF MEFV IL6
8 juvenile rheumatoid arthritis 31.7 TNF IL6 IL1B IL10 CXCL8 CRP
9 diverticulitis 31.7 TNF IL6 CRP ALB
10 intestinal perforation 31.6 TNF IL6 CRP ALB
11 ileus 31.5 TNF IL6 IL1B IL10 CRP CCL2
12 toxic shock syndrome 31.4 TNF TLR2 LBP IL6 IL1B IL10
13 typhoid fever 31.3 TNF IL6 IL1B CRP ALB
14 end stage renal disease 31.3 TNF IL6 IL1B IL10 CRP CCL2
15 hepatic encephalopathy 31.3 TNF IL6 ALB
16 liver cirrhosis 31.3 TNF TLR2 LBP IL6 IL1B IL10
17 duodenal ulcer 31.3 TNF IL6 IL1B IL10 CXCL8
18 peptic ulcer disease 31.2 TNF IL1B IL10 CXCL8
19 salpingitis 31.2 TNF TLR2 IL6 CRP
20 peptic ulcer perforation 31.2 CRP ALB
21 intussusception 31.1 IL6 CRP ALB
22 abdominal tuberculosis 31.1 TNF CRP ALB ADA
23 liver disease 31.1 TNF IL6 IL1B CXCL8 ALB
24 gastric ulcer 31.1 TNF IL6 IL1B CXCL8
25 haemophilus influenzae 31.1 TNF TLR2 CXCL8
26 gastroenteritis 31.1 TNF IL6 IL1B IL10 CXCL8 CRP
27 enterocolitis 31.1 TNF IL6 IL10 CXCL8 CRP
28 intestinal tuberculosis 31.1 TNF CRP ALB
29 fasciitis 31.1 TNF IL6 CXCL8
30 glomerulonephritis 31.1 IL1B CCL2 B2M ALB
31 cellulitis 31.0 TNF IL6 CRP ALB
32 pleural empyema 31.0 IL6 CRP ALB ADA
33 endometritis 31.0 TNF IL6 IL1B CXCL8
34 acute pancreatitis 31.0 TNF IL6 IL1B IL10 CXCL8 CRP
35 pelvic inflammatory disease 30.9 TLR2 CRP CCL2
36 streptococcal toxic-shock syndrome 30.9 TNF IL6 CXCL8
37 lymphadenitis 30.9 TNF IL1B IL10 CXCL8 CRP
38 disseminated intravascular coagulation 30.9 TNF IL6 IL10 CRP
39 alcoholic liver cirrhosis 30.9 TNF IL6 IL1B IL10 CXCL8 ALB
40 pancreatitis 30.9 TNF TMEM67 IL6 IL1B IL10 CRP
41 compartment syndrome 30.9 TNF IL6 CRP ALB
42 candidiasis 30.9 TNF TLR2 IL6 IL1B IL10 CXCL8
43 necrotizing fasciitis 30.8 IL6 IL1B CXCL8 CRP ALB
44 ileitis 30.8 TNF TLR2 IL6
45 pulmonary edema 30.8 TNF IL1B IL10 CXCL8 CRP
46 diarrhea 30.8 TNF IL6 IL1B IL10 CXCL8 ALB
47 varicose veins 30.8 TNF IL6 CXCL8
48 mesenteric lymphadenitis 30.8 LBP IL1B CRP
49 mycobacterium abscessus 30.8 TNF TLR2 CXCL8
50 colitis 30.8 TNF TLR2 IL6 IL1B IL10 CXCL8

Comorbidity relations with Peritonitis via Phenotypic Disease Network (PDN): (show all 12)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Vascular Insufficiency of Intestine
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Intestinal Obstruction
Intestinal Perforation Paralytic Ileus
Protein-Energy Malnutrition Respiratory Failure

Graphical network of the top 20 diseases related to Peritonitis:



Diseases related to Peritonitis

Symptoms & Phenotypes for Peritonitis

MGI Mouse Phenotypes related to Peritonitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.27 ADA ALB AQP1 B2M CRP CXCL2
2 cellular MP:0005384 10.21 ADA ALB B2M FCGR1A IL10 IL6
3 hematopoietic system MP:0005397 10.21 ADA AQP1 B2M CXCL2 FCGR1A IL10
4 immune system MP:0005387 10.19 ADA ALB AQP1 B2M CCL2 CRP
5 homeostasis/metabolism MP:0005376 10.17 ADA ALB AQP1 B2M CRP IL10
6 digestive/alimentary MP:0005381 10.01 ADA ALB B2M IL10 IL6 TLR2
7 liver/biliary system MP:0005370 9.85 ADA ALB B2M IL10 IL6 LBP
8 neoplasm MP:0002006 9.5 ALB B2M IL10 IL1B IL6 TLR2
9 skeleton MP:0005390 9.4 ADA CXCL2 FCGR1A IL10 IL1B IL6

Drugs & Therapeutics for Peritonitis

Drugs for Peritonitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 576)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
2
Lactulose Approved Phase 4 4618-18-2 11333
3
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
4
Enalaprilat Approved Phase 4 76420-72-9 6917719
5
Hydralazine Approved Phase 4 86-54-4 3637
6
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
7
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
8
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
9
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
10
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
11
Simvastatin Approved Phase 4 79902-63-9 54454
12
Atorvastatin Approved Phase 4 134523-00-5 60823
13
Linagliptin Approved Phase 4 668270-12-0 10096344
14
Insulin lispro Approved Phase 4 133107-64-9
15
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
16
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
17
Cefoxitin Approved Phase 4 35607-66-0 441199
18
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
19
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
20
Cefepime Approved, Investigational Phase 4 88040-23-7 5479537
21
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
22
Acetaminophen Approved Phase 4 103-90-2 1983
23
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
24
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
25
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
26
Norfloxacin Approved Phase 4 70458-96-7 4539
27
Propranolol Approved, Investigational Phase 4 525-66-6 4946
28
Dalbavancin Approved, Investigational Phase 4 171500-79-1, 91097-81-3 122186
29
Teicoplanin Approved, Investigational Phase 4 61036-62-2
30
Tigecycline Approved Phase 4 220620-09-7 5282044
31
Caspofungin Approved Phase 4 162808-62-0, 179463-17-3 468682 2826718
32
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
33
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
34
Alendronate Approved Phase 4 121268-17-5, 66376-36-1 2088
35
Goserelin Approved Phase 4 65807-02-5 47725 5311128
36
Sodium citrate Approved, Investigational Phase 4 68-04-2
37
Loperamide Approved Phase 4 53179-11-6 3955
38
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
39
Cinacalcet Approved Phase 4 226256-56-0 156419
40
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
41
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
42
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
43
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
44
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
45
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
46
Febuxostat Approved Phase 4 144060-53-7 134018
47
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
48
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
49
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
50
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833

Interventional clinical trials:

(show top 50) (show all 1481)
# Name Status NCT ID Phase Drugs
1 The Clinical Use of Probiotics in the Uremia Patients Under Chronic Peritoneal Dialysis Unknown status NCT01076426 Phase 4 Pro-biotics
2 Effects of Non-Glucose-Based Peritoneal Dialysis Solution "EXTRANEAL" on Changes in Leptin Levels and Sympathetic Activity Induced by Conventional Glucose-Based Dialysate "DIANEAL" in Patients on Peritoneal Dialysis Unknown status NCT01228279 Phase 4
3 Granulocyte Colony Stimulating Factor Plus N-Acetyl Cysteine In Severe Alcoholic Hepatitis Unknown status NCT02971306 Phase 4 standard medical therapy;G-CSF;n-Acetylcysteine
4 The Effect of Enalapril and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients Unknown status NCT01041963 Phase 4 Enalapril;Enalapril plus Losartan;Placebo
5 The Effect of Aliskiren and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients Unknown status NCT01305850 Phase 4 placebo;Aliskiren;Aliskiren plus Losartan;Enalapril plus Losartan
6 Effect of Ursodeoxycholic Acid on Peritoneal Function in Patients on Peritoneal Dialysis Unknown status NCT02338635 Phase 4 Ursodeoxycholic Acid
7 A Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis Unknown status NCT00761098 Phase 4 Standard Care;Experimental
8 Antibiotics vs.Surgery in Acute Appendicitis;an Intention to Treat Prospective Randomised Study. The ASAA-study Unknown status NCT01421901 Phase 4 Ertapenem
9 PROPHYlactic Implantation of BIOlogic Mesh in Peritonitis (PROPHYBIOM) Unknown status NCT02277262 Phase 4
10 Can Alendronate Suppress Aortic and Coronary Artery Calcification and Improve Bone Mineral Density in Chronic Peritoneal Dialysis Patients? Unknown status NCT00299572 Phase 4 alendronate (Fosamax)
11 Effects of Cholecalciferol on Osteoprotegerin Levels and Other Clinical Outcomes in Chronic Kidney Disease Patients on Peritoneal Dialysis: a Randomized Controlled Trial Unknown status NCT02598635 Phase 4 Cholecalciferol;Placebo
12 Comparison of Intravenous Lidocaine and Intraperitoneal Lidocaine Irrigation for Effective Pain Relief After Laparoscopic Cholecystectomy: A Prospective, Randomized, Double-blind, Placebo-controlled Study Unknown status NCT01608373 Phase 4 Intravenous lidocaine injection;Intraperitoneal lidocaine irrigation group;Intravenous normal saline injection
13 Postoperative Analgesic Efficacy of the Pulmonary Recruitment Maneuver Compared to Intraperitoneal Hydrocortisone in Laparoscopic Gynecological Surgery Unknown status NCT03845608 Phase 4
14 Randomised, Controlled Clinical Study With Patients With Endometriosis and the Desire to Have Children - Comparison Between Peritoneal Ablation by Excision Only and Excision With the Use of an Adhesionbarrier Unknown status NCT02165917 Phase 4
15 A Prospective,Single-arm,Multicenter Study to Evaluate the Efficacy and Safety of Mircera in Peritoneal Patients Who Already Had Been Treated With ESA Unknown status NCT01807481 Phase 4 Mircera
16 Simvastatin Effect on Endothelium Dependent Venodilation in Chronic Renal Failure Patients Treated by Peritoneal Dialysis Unknown status NCT00291863 Phase 4 Simvastatin
17 A Randomized Prospective Trial of N-acetyl Cystein in Patients With Peritoneal Dialysis Unknown status NCT01111422 Phase 4 N-acetylcysteine
18 Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients (ALEVENT) Unknown status NCT01503671 Phase 4 Atorvastatin
19 An Evaluation of the Efficacy and Safety of a Polyethylene Glycol (PEG) Based Bowel Protocol for the Management of Constipation in Peritoneal Dialysis Patients: A Pilot Study Unknown status NCT03148002 Phase 4 Current Bowel Protocol (senna/lactulose);PEG Bowel Protocol (PEG/lactulose)
20 A Randomized, Open, Controlled, Parallel Group Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy Unknown status NCT03320031 Phase 4 Linagliptin;Humalog Mix 75/25
21 A Randomized Controlled Double Blind Study Using Mupirocin Versus Polysporin Triple for the Prevention of Catheter-related Infections in Patients Treated With Peritoneal Dialysis Completed NCT00400595 Phase 4 Mupirocin ointment;Polysporin Triple
22 Effect of Icodextrin on the Treatment Outcome of Peritoneal Dialysis Patients Completed NCT01044446 Phase 4 Icodextrin;glucose-based peritoneal dialysate
23 Randomized Controlled Trial Comparing Residual Kidney Function in Patients Undergoing Three or Four Exchanges CAPD Completed NCT01637792 Phase 4
24 The Effect of Balance PD Solution on the Peritoneal Membrane in Patients on Automated Peritoneal Dialysis Completed NCT01753154 Phase 4 Solution B (balance PD solution);Solution A (conventional PD solution)
25 Efficacy and Safety of a 7.5% Icodextrin Peritoneal Dialysis Solution in Once-Daily Long Dwell Exchange in Continuous Ambulatory Peritoneal Dialysis Patients, Compare to 2.5% Dianeal Peritoneal Dialysis Solution. Completed NCT00725517 Phase 4 Icodextrin
26 A Multicenter, Randomized, Controlled Trial Comparing Cefepime Monotherapy Versus Combination of Cefazolin Plus Ceftazidime for Empirical Treatment of CAPD-associated Peritonitis Completed NCT02872038 Phase 4 Cefepime;Cefazolin plus Ceftazidime
27 Bacteria Endotoxin in Peritoneal Dialysis Effluent as a Predictor of Relapsing, Recurrent, and Repeat Peritonitis Completed NCT01817309 Phase 4
28 Offene, Monozentrische, Nicht Kontrollierte Und Nicht Randomisierte Phase IV-Studie Zur Bestimmung Der Pharmakokinetik Von Carbapenemen in adipösen Patienten. Completed NCT01407965 Phase 4
29 Surgical Pain Control With Ropivacaine by Atomized Delivery Completed NCT01480089 Phase 4 Intraperitoneal Ropivacaine (AIR);Atomized Intraperitoneal Saline (AIS)
30 Effects of Angiotensin Converting Enzyme Inhibitors on Peritoneal Protein Loss and Solute Transport in Peritoneal Dialysis Patients Completed NCT01575652 Phase 4
31 Randomized Trial on Intravenous Antibiotics With Adjunctive Lavage for Severe Peritoneal-dialysis Related Peritonitis Completed NCT02926846 Phase 4 Intravenous vancomycin & gentamicin with adjunctive lavage;Intraperitoneal vancomycin & gentamicin
32 Effect of Different Dialysis Dosage on Prognosis in Maintenance Peritoneal Dialysis Patients - A Prospective, Randomized, Controlled, Multi-center Clinical Study Completed NCT00912821 Phase 4 6 L dialysate;8 L dialysate
33 Phase 4 Study of Primary Use of the Vacuum Assisted Laparostomy in Treatment of Severe Peritonitis Completed NCT01531543 Phase 4
34 Targeting Peroxisome Proliferator-Activated Receptor-Gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients? Completed NCT00745225 Phase 4 Pioglitazone;placebo comparator
35 Influence of Dialysate Temperature on Peritoneal Creatinine Clearance in Patients in Peritoneal Dialysis Completed NCT04302649 Phase 4 peritoneal dialysate at 37°C temperature
36 The Efficacy of Prolonged Antibiotic Therapy for the Prevention of Relapsing Peritonitis in Peritoneal Dialysis Patients With High Dialysis Effluent Bacterial DNA Fragment Levels Completed NCT02593201 Phase 4 Extended antibiotics (cefazolin or ceftazidime);Usual antibiotics (cefazolin or ceftazidime)
37 Randomized Double-Blid Placebo Controlled Trial Assessing Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis In Advanced Cirrhosis Completed NCT00359853 Phase 4 Oral norfloxacin
38 Open-label, Randomized, Controlled, With Blind Assessor, Study to Assess Efficacy and Safety of Rheosorbilact®, Solution for Infusion, in Comparison With Ringer's Lactate,Solution for Infusion, in a Complex Therapy of Peritonitis. Completed NCT03771170 Phase 4 Rheosorbilact®;Ringer lactate
39 Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients Completed NCT02940730 Phase 4 Dalbavancin via Intravenous Administration;Dalbavancin via Intraperitoneal Administration
40 Pharmacokinetic Study on Echinocandins for Patients With Septic Shock Following Secondary Peritonitis Completed NCT02805049 Phase 4 Echinocandins
41 Comparison of Efficacy of Cefotaxime, Ceftriaxone, and Ciprofloxacin for the Treatment of Spontaneous Bacterial Peritonitis in Patients With Liver Cirrhosis Completed NCT01265173 Phase 4 Cefotaxime;Ceftriaxone;Ciprofloxacin
42 Comparison of Daily Norfloxacin Versus Weekly Ciprofloxacin for the Prevention of Spontaneous Bacterial Peritonitis in Cirrhotic Patients Completed NCT01542801 Phase 4 Norfloxacin;ciprofloxacin
43 A Multicenter, Open-Label, Randomized Comparative Study of Tigecycline vs Ceftriaxone Sodium Plus Metronidazole for the Treatment of Hospitalized Subjects With Complicated Intra-abdominal Infection Completed NCT00230971 Phase 4 tigecycline;ceftriaxone plus metronidazole
44 A Multicenter, Open-Label, Randomized Comparative Study of Tigecycline vs Ceftriaxone Sodium Plus Metronidazole for the Treatment of Hospitalized Subjects With Complicated Intra-abdominal Infection Completed NCT00195351 Phase 4 tigecycline;ceftriaxone sodium + metronidazole
45 Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension Completed NCT01059396 Phase 4 propranolol;carvedilol;placebo
46 EXerCise Introduction To Enhance Performance in Dialysis: the EXCITE Study Completed NCT01255969 Phase 4
47 A Study to Evaluate the Effects of Icodextrin vs 2.5% Dianeal Used for the Long Dwell in Apd: a Randomized, Open-label Clinical Trial to Analyse the Insulin Resistance Using the Homa Index in Prevalent, Non-diabetic Patients Completed NCT01021878 Phase 4
48 Phase 4 Study of Recombinant Hepatitis B Vaccine in Peritoneal Dialysis Subjects Completed NCT00125775 Phase 4
49 A Randomized Trial of Daily Chlorhexidine Care at the Exit Site in Peritoneal Dialysis Patients for Bacterial Decolonization and Prevention of Infection Completed NCT02446158 Phase 4 Chlorhexidine gluconate
50 Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis Completed NCT00939952 Phase 4 ertapenem

Search NIH Clinical Center for Peritonitis

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Albumin Human, USP
ALBUMIN,AGGREGATED
ALBUMIN,EGG
ALBUMIN,HUMAN INJ
ALBUMIN,MICROSPHERE HUMAN SERUM

Genetic Tests for Peritonitis

Anatomical Context for Peritonitis

MalaCards organs/tissues related to Peritonitis:

40
Colon, Neutrophil, Small Intestine, Liver, Endothelial, Pancreas, Appendix

Publications for Peritonitis

Articles related to Peritonitis:

(show top 50) (show all 30204)
# Title Authors PMID Year
1
Mortality and risk stratification in patients with Clostridium difficile-associated diarrhoea. 61 54
19508548 2010
2
Predictors of patient survival in continuous ambulatory peritoneal dialysis: 10-year experience in 2 major centers in Tehran. 54 61
20081304 2010
3
Peritonitis from peg tube insertion in surgical intensive care unit patients: identification of risk factors and clinical outcomes. 61 54
19430836 2009
4
Endothelial dysfunction in peritoneal dialysis patients with and without failed renal transplants. 61 54
19917360 2009
5
AGE-modified albumin containing infusion solutions boosts septicaemia and inflammation in experimental peritonitis. 54 61
19401390 2009
6
Peritoneal resorption capacity for the inflammatory mediators in acute experimental Staphylococcus aureus peritonitis. 54 61
19669960 2009
7
Primary peritonitis due to brucellosis mimicking tuberculous peritonitis. 61 54
19530047 2009
8
Albumin administration in patients with severe sepsis due to secondary peritonitis. 54 61
19467947 2009
9
[Peritonitis in the course of peritoneal dialisis caused by Haemophilus influenzae with BLNAR phenotype]. 54 61
19580200 2009
10
Effect of the combination of fibrin glue and growth hormone on intestinal anastomoses in a pig model of traumatic shock associated with peritonitis. 61 54
19132439 2009
11
Fungal peritonitis in peritoneal dialysis: risk factors and prognosis. 61 54
19142806 2009
12
Systemic and intraperitoneal proinflammatory cytokine profiles in patients on continuous ambulatory peritoneal dialysis. 61 54
19886317 2009
13
Is decline in serum albumin an ominous sign for subsequent peritonitis in peritoneal dialysis patients? 54 61
19886340 2009
14
[The prognostic role of interleukin-6 in peritoneal exudate of patients with diffuse peritonitis]. 54 61
20020622 2009
15
Concentration of adipokines in peritoneal effluent: a new marker of acute peritonitis in peritoneal dialysis patients? 61 54
18708547 2008
16
Clinical characteristics of lower bowel perforation with chronic renal failure. 54 61
19102359 2008
17
The relationship of p1 and lewis antigens with peritoneal dialysis-related Escherichia coli peritonitis. 61 54
18552251 2008
18
The outcome for pediatric patients on peritoneal dialysis. 54 61
18587728 2008
19
[Peritonitis related to peritoneal dialysis: evaluation of 179 attacks]. 54 61
18697424 2008
20
TLR2-dependent MyD88 signaling contributes to early host defense in murine Enterococcus faecium peritonitis. 54 61
18354210 2008
21
Relation of demographic, clinic and biochemical parameters to peritonitis in peritoneal dialysis. 61 54
18336516 2008
22
Fas expression on peritoneal macrophages during continuous ambulatory peritoneal dialysis peritonitis. 61 54
18350449 2008
23
A leptin serum concentration less than 10 ng/ml is a predictive marker of outcome in patients with moderate to severe secondary peritonitis. 54 61
18525209 2008
24
Proteomic analysis of peritoneal dialysate fluid in patients with dialysis-related peritonitis. 61 54
18791950 2008
25
Streptococcus salivarius bacteremia and spontaneous bacterial peritonitis in liver transplantation candidates. 54 61
17969206 2007
26
Reduced residual renal function is a risk of peritonitis in continuous ambulatory peritoneal dialysis patients. 54 61
17517797 2007
27
Influence of peritoneal dialysis training nurses' experience on peritonitis rates. 61 54
17699477 2007
28
Peritonitis, peritoneal inflammation and membrane permeability: a longitudinal study of dialysate and serum MCP-1 in stable patients on peritoneal dialysis. 61 54
17557268 2007
29
Collagenase 2/matrix metalloproteinase 8 in critically ill patients with secondary peritonitis. 54 61
17224788 2007
30
Adherence to peritoneal dialysis training schedule. 61 54
17035375 2007
31
Comparison of incidence of peritonitis between peritoneal dialysis solution types. 54 61
17409770 2007
32
Impact of nutritional status on peritonitis in CAPD patients. 54 61
17179509 2007
33
Systemic and intraperitoneal proinflammatory cytokines profiles in patients on chronic peritoneal dialysis. 54 61
18928158 2007
34
Clinical predictors of ongoing infection in secondary peritonitis: systematic review. 61 54
17102920 2006
35
Compartmentalization of interleukin-6 response in a patient with septic meningococcal peritonitis. 61 54
16988004 2006
36
Anti-inflammatory effects of a novel peptide designed to bind with NF-kappaB p50 subunit. 54 61
17049124 2006
37
Malnutrition-inflammation score is a useful tool in peritoneal dialysis patients. 54 61
17047239 2006
38
Adenosine is upregulated during peritonitis and is involved in downregulation of inflammation. 54 61
16788688 2006
39
Risk factors of first peritonitis episode in Thai CAPD patients. 54 61
17044465 2006
40
Survival and technical failure in a large cohort of Thai CAPD patients. 61 54
17044460 2006
41
Mast cell chymase induces expression of chemokines for neutrophils in eosinophilic EoL-1 cells and mouse peritonitis eosinophils. 61 54
16690053 2006
42
Peritonitis in childhood: clinical relevance of cytokines in the peritoneal exudate. 61 54
16685614 2006
43
Timely transfer of peritoneal dialysis patients to hemodialysis improves survival rates. 54 61
16429841 2006
44
Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. 54 61
16538876 2006
45
Dialysate CA125 levels in children on continuous peritoneal dialysis. 54 61
16133054 2005
46
Risk factors for peritonitis in pediatric peritoneal dialysis: a single-center study. 61 54
16082548 2005
47
The impact of topical mupirocin on peritoneal dialysis infection in Singapore General Hospital. 61 54
16046516 2005
48
[A contemporary situation in the antimicrobial treatment of the secondary peritonitis]. 54 61
16250620 2005
49
The impact of topical mupirocin on peritoneal dialysis infection rates in Singapore General Hospital. 61 54
15855200 2005
50
A risk analysis of continuous ambulatory peritoneal dialysis-related peritonitis. 61 54
16022095 2005

Variations for Peritonitis

ClinVar genetic disease variations for Peritonitis:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TMEM67 NM_153704.6(TMEM67):c.1321C>T (p.Arg441Cys) SNV Likely pathogenic 217725 rs752362727 8:94798483-94798483 8:93786255-93786255
2 TMEM67 NM_153704.6(TMEM67):c.1843T>C (p.Cys615Arg) SNV Likely pathogenic 1383 rs201893408 8:94808198-94808198 8:93795970-93795970

Expression for Peritonitis

Search GEO for disease gene expression data for Peritonitis.

Pathways for Peritonitis

Pathways related to Peritonitis according to GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.07 TNF TLR2 MUC16 MEFV LBP ITGB2
2
Show member pathways
13.86 TNF ITGB2 ITGAM IL6 IL1B IL10
3
Show member pathways
13.58 TNF ITGB2 ITGAM IL6 IL1B IL10
4
Show member pathways
13.51 TNF TLR2 ITGB2 ITGAM IL6 IL1B
5
Show member pathways
13.41 TNF LBP ITGB2 ITGAM IL6 IL1B
6
Show member pathways
13.35 TNF IL6 IL1B IL10 CXCL8 CXCL2
7
Show member pathways
13.16 TNF TLR2 LBP IL6 IL1B IL10
8
Show member pathways
13.03 TNF TLR2 IL6 IL1B CXCL8 CXCL2
9
Show member pathways
12.96 TNF ITGB2 IL6 IL1B IL10 CXCL8
10
Show member pathways
12.94 TNF TLR2 IL6 IL1B CXCL8 CCL2
11 12.88 TNF TLR2 IL6 IL1B CCL2 B2M
12
Show member pathways
12.78 TNF TLR2 IL6 IL1B CXCL8
13
Show member pathways
12.76 TNF TLR2 IL6 IL1B CXCL8
14 12.69 TNF TLR2 ITGB2 IL1B IL10 CCL2
15
Show member pathways
12.66 TNF TLR2 IL6 IL1B IL10
16
Show member pathways
12.66 TNF TLR2 IL6 IL1B IL10
17
Show member pathways
12.64 TNF IL6 IL1B IL10 CCL2
18
Show member pathways
12.46 TNF TLR2 IL6 IL1B CXCL8 CXCL2
19
Show member pathways
12.45 TNF IL6 IL10 CXCL8 CXCL2 CCL2
20
Show member pathways
12.45 TNF IL6 IL1B CRP CCL2 ALB
21
Show member pathways
12.39 TNF LBP IL6 IL1B CXCL8
22 12.38 TNF ITGB2 IL6 B2M
23
Show member pathways
12.38 TNF TLR2 ITGB2 ITGAM IL1B IL10
24 12.35 TNF MEFV IL6 IL1B CXCL8 CXCL2
25
Show member pathways
12.32 TNF IL6 IL1B IL10 CXCL8
26 12.31 ITGAM IL6 FCGR1A CXCL8
27
Show member pathways
12.31 TNF TLR2 IL6 CXCL8
28
Show member pathways
12.31 TNF TLR2 LBP IL6 IL1B CXCL8
29 12.29 TNF IL6 IL1B IL10 CXCL8
30 12.28 TNF TLR2 LBP ITGB2 ITGAM IL6
31
Show member pathways
12.27 TNF IL6 IL1B IL10
32 12.2 TLR2 ITGB2 ITGAM FCGR1A
33 12.19 TNF MEFV IL6 IL1B IL10 CXCL8
34 12.12 TNF IL6 IL1B CXCL2 CCL2
35 12.1 TNF IL6 IL1B CXCL8 CXCL2 CCL2
36 12.07 TNF ITGAM IL6 IL10
37 12.07 TNF LBP IL1B CXCL8 CXCL2
38 12.05 TNF IL6 IL1B CXCL8 CCL2
39 12.04 TNF ITGAM IL6 IL1B FCGR1A
40 11.98 ITGB2 ITGAM IL10 FCGR1A
41 11.97 TNF LBP ITGB2 ITGAM IL6 IL1B
42 11.92 TLR2 ITGB2 ITGAM FCGR1A
43
Show member pathways
11.9 TNF TLR2 IL6 IL1B IL10
44 11.89 TNF ITGAM IL1B IL10
45 11.89 TNF TLR2 ITGB2 IL6 IL1B CXCL8
46 11.88 TNF ITGAM IL6 IL1B IL10
47 11.86 TNF ITGB2 ITGAM IL6 IL1B IL10
48 11.82 TNF TLR2 ITGB2 IL6 IL10
49
Show member pathways
11.79 TNF IL6 IL1B CXCL8 CXCL2
50 11.77 TNF IL6 IL1B CXCL8 CXCL2 CCL2

GO Terms for Peritonitis

Cellular components related to Peritonitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 TNF MUC16 LBP IL6 IL1B IL10
2 external side of plasma membrane GO:0009897 9.72 TNF ITGB2 ITGAM B2M ADA
3 cell surface GO:0009986 9.7 TNF TLR2 LBP ITGB2 ITGAM B2M
4 extracellular space GO:0005615 9.47 TNF MUC16 LBP ITGAM IL6 IL1B
5 integrin alphaM-beta2 complex GO:0034688 9.26 ITGB2 ITGAM

Biological processes related to Peritonitis according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.19 TLR2 MEFV LBP ITGAM FCGR1A B2M
2 innate immune response GO:0045087 10.12 TLR2 MEFV LBP ITGAM FCGR1A CRP
3 negative regulation of cell proliferation GO:0008285 10.1 TLR2 IL6 IL1B IL10 CXCL8
4 positive regulation of gene expression GO:0010628 10.1 TNF TLR2 IL6 IL1B CXCL8 CRP
5 immune response GO:0006955 10.02 TNF TLR2 IL6 IL1B IL10 FCGR1A
6 response to lipopolysaccharide GO:0032496 9.98 TLR2 LBP IL1B IL10
7 receptor-mediated endocytosis GO:0006898 9.98 ITGB2 ITGAM FCGR1A ALB
8 positive regulation of angiogenesis GO:0045766 9.97 ITGB2 IL1B CXCL8 AQP1
9 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.96 TNF TLR2 ITGB2 IL6 IL1B
10 positive regulation of DNA-binding transcription factor activity GO:0051091 9.92 TNF IL6 IL1B IL10
11 neutrophil chemotaxis GO:0030593 9.91 ITGB2 CXCL8 CXCL2 CCL2
12 regulation of insulin secretion GO:0050796 9.89 TNF IL6 IL1B
13 chemokine-mediated signaling pathway GO:0070098 9.89 CXCL8 CXCL2 CCL2
14 defense response to Gram-positive bacterium GO:0050830 9.89 TNF TLR2 LBP IL6 CRP
15 cellular response to organic cyclic compound GO:0071407 9.88 TNF IL1B CCL2
16 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.88 TNF TLR2 IL1B
17 response to glucocorticoid GO:0051384 9.87 TNF IL6 IL10
18 humoral immune response GO:0006959 9.87 TNF IL6 CCL2
19 cellular response to lipopolysaccharide GO:0071222 9.86 TNF LBP IL6 IL1B IL10 CXCL8
20 positive regulation of nitric oxide biosynthetic process GO:0045429 9.85 TNF ITGB2 IL1B
21 positive regulation of interleukin-6 production GO:0032755 9.85 TNF TLR2 LBP IL6 IL1B
22 protein kinase B signaling GO:0043491 9.83 TNF IL1B CCL2
23 positive regulation of chemokine production GO:0032722 9.83 TNF TLR2 LBP IL6
24 acute-phase response GO:0006953 9.82 LBP IL6 CRP
25 positive regulation of JAK-STAT cascade GO:0046427 9.81 TNF IL6 IL10
26 positive regulation of interleukin-8 production GO:0032757 9.8 TNF TLR2 LBP IL6 IL1B
27 positive regulation of superoxide anion generation GO:0032930 9.79 ITGB2 ITGAM CRP
28 toll-like receptor 4 signaling pathway GO:0034142 9.79 LBP ITGB2 ITGAM
29 microglial cell activation GO:0001774 9.78 TNF TLR2 ITGB2 ITGAM